Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
76.86 CHF | -1.00% |
|
-0.77% | -.--% |
07:43pm | Novartis to Close Technical Research Facility in San Diego, California; 100 Jobs Affected | MT |
04:28pm | Novartis to Close Research Facility in San Diego, California; 100 Jobs Affected | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 223B | - | ||
+60.25% | 846B | C+ | ||
+38.56% | 628B | B | ||
-4.49% | 360B | C+ | ||
+18.30% | 322B | B- | ||
+9.64% | 297B | C+ | ||
+14.15% | 240B | B+ | ||
+3.11% | 224B | A+ | ||
+12.87% | 173B | C+ | ||
-0.45% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NOVN Stock
- 0QM7 Stock
- Ratings Novartis AG